Home > Boards > US Listed > Biotechs > iBio, Inc. (IBIO)

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201 Source:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Thai5533 Member Profile
 
Followed By 6
Posts 800
Boards Moderated 0
Alias Born 12/18/18
160x600 placeholder
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 10/23/2020 5:21:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2020 4:06:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/16/2020 4:06:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:10:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:10:08 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:09:10 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/16/2020 6:08:32 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/16/2020 6:07:29 AM
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors GlobeNewswire Inc. - 10/15/2020 4:05:10 PM
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors GlobeNewswire Inc. - 10/15/2020 7:30:10 AM
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors GlobeNewswire Inc. - 10/14/2020 4:05:10 PM
Annual Report (10-k) Edgar (US Regulatory) - 10/13/2020 5:19:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 4:28:18 PM
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020 GlobeNewswire Inc. - 10/13/2020 4:05:10 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/13/2020 7:00:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2020 4:31:28 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/5/2020 8:32:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/5/2020 8:01:44 AM
iBio Regains Compliance with NYSE American Continued Listing Standards GlobeNewswire Inc. - 10/5/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2020 7:31:01 AM
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System GlobeNewswire Inc. - 10/2/2020 7:00:10 AM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 9/28/2020 6:07:20 AM
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201 GlobeNewswire Inc. - 9/9/2020 8:45:10 AM
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic GlobeNewswire Inc. - 8/28/2020 7:15:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/13/2020 4:55:48 PM
Thai5533   Wednesday, 09/09/20 08:58:55 AM
Re: None
Post # of 25156 
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

Source: GlobeNewswire Inc.

iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has selected IBIO-201, its LicKM™-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection.
iBio previously announced that preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute (“IDRI”), induced anti-SARS-CoV-2 antibodies. Additional data from cell-based pseudovirus neutralization assay testing demonstrate that IBIO-201 induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice.

“Our decision to evaluate IBIO-200 and IBIO-201 in tandem, and in combination with multiple adjuvants, proved beneficial given the results observed with IBIO-201 in preclinical studies,” said Tom Isett, Chairman & CEO of iBio. “While IBIO-201 produced significantly higher anti-spike neutralizing antibody titers than IBIO-200, we are still encouraged by the potential of IBIO-200.”

Mr. Isett continued, “We plan to conduct more focused studies on each of IBIO-200 and IBIO-201, with the goal of advancing IBIO-201 to toxicology studies ahead of planned clinical development. Meanwhile, we intend to continue preclinical development of IBIO-200 and our virus-like particle platform as a potential ‘plug-and-play’ vaccine development system.”

iBio continues to work with IDRI and the Texas A&M University System, and expects to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.

About iBio’s COVID-19 Vaccine Development Programs

On March 11, 2020, the Company filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its COVID-19 vaccine platforms. The Company subsequently announced its virus-like particle (“VLP”) program (“IBIO-200”) and LicKM™-Subunit vaccine program (“IBIO-201”) on March 18, and June 3, 2020, respectively, and pre-clinical studies were subsequently initiated. On August 27, 2020, the Company secured exclusive worldwide rights to an ACE2-Fc antibody therapeutic. On September 9, 2020, iBio announced that it intended to advance IBIO-201 while it continued to evaluate IBIO-200. If any of the COVID-19 biopharmaceutical development program(s) move into clinical trials, iBio has the capability to manufacture product candidates at clinical and commercial scales in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency [DARPA], iBio’s FastPharming® Facility was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences